Evolus, Inc. (EOLS)

Market Cap	839.35M
Revenue (ttm)	266.27M
Net Income (ttm)	-50.42M
Shares Out	63.59M
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	778,748
Open	13.10
Previous Close	12.96
Day's Range	12.75 - 13.21
52-Week Range	9.25 - 17.82
Beta	1.28
Analysts	Strong Buy
Price Target	24.40 (+84.85%)
Earnings Date	Mar 4, 2025

About EOLS

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 8, 2018
• Employees: 332
• Stock Exchange: NASDAQ
• Ticker Symbol: EOLS
• Website: https://www.evolus.com

Financial Performance

In 2024, Evolus's revenue was $266.27 million, an increase of 31.76% compared to the previous year's $202.09 million. Losses were -$50.42 million, -18.26% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price forecast is $24.4, which is an increase of 84.85% from the latest price.

Price Target

$24.4

(84.85% upside)

Analyst Consensus: Strong Buy